After approval of DGCI, many pharma companies are ready to launch Malnupiravir for treatment of Covid-19

0
Malnupiravir

New Delhi: Leading pharmaceutical companies… Cipla, Sun Pharma, Dr. Reddy’s, Torrent Pharma, Optimus Pharma, and Hetero Pharmaceutical have said that they have received an emergency response from the Drug Controller General of India (DGCI) for Malnupiravir, an antiviral drug useful in the treatment of COVID-19, in the country. After getting permission for use, we are ready to launch it in the market as soon as possible.

Cipla said it plans to launch the drug under the brand name Cipmolnu. Cipla Managing Director and Global Chief Executive Officer Umang Vohra said in a statement that this is a new offering as part of providing essential therapies for the treatment of Kovid. Apart from India, there are plans to make this drug available in more than 100 countries of low and middle income.

Earlier in the day, the government allowed the controlled use of Malanupiravir (tablet) in the treatment of Covid-19 in an emergency. It will be given to adult patients and people at higher risk of disease.

Union Health Minister Mansukh Mandaviya tweeted, “To further strengthen the fight against COVID-19, the Central Drugs Standard Control Organization (CDSCO) has given three clearances in a day. The Covovax and Corbevax vaccines and the drug ‘Molnupiravir’ have been permitted for emergency use subject to certain conditions.”

Malnupiravir

Pharmaceutical company Sun Pharma has also received DCGI’s nod to market Malnupiravir. The company on Tuesday said its subsidiary has received EUA for manufacturing and marketing from DCGI. Optimus Pharma has also announced the launch of Molnupiravir in the Indian market in a day or two. Torrent Pharma said that it will introduce Molluprevir, a drug useful in the treatment of Covid-19, under the brand name Molnutter in India. The company had earlier entered into an agreement with MSD for the manufacturing and distribution of Malanupiravir.

Hyderabad-based pharmaceutical company Hetero Pharmaceuticals said it has received permission from DCGI to manufacture and market 200 mg Molluprevir capsules. The company will market this capsule under the brand name Movafor. Hetero said in a statement that it will be produced at the company’s plants in Telangana and Himachal Pradesh. Dr. Reddy has also announced the launch of a 200 mg capsule of Malnupiravir. The Hyderabad-based company said that it will launch this drug under the brand name Molflu in the Indian market.

Advertisement